Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
The GOZILA study, published in Nature Medicine, demonstrates that using Guardant360 CDx liquid biopsy for targeted cancer treatment can significantly extend patient survival. The study, involving 4,037 patients with advanced gastrointestinal tumors, found that 24% of participants received targeted treatment based on the test results. Patients who received personalized treatment guided by liquid biopsy results lived approximately twice as long as those who did not, with a median survival of 18.6 months compared to 9.9 months. This research, led by the National Cancer Center Hospital East in Japan, suggests a potential paradigm shift in cancer treatment by demonstrating the survival-extending effect of liquid biopsy-based personalized cancer treatment across various cancer types.
Guardant Health (Nasdaq: GH) announced its participation in the European Society for Medical Oncology Congress (ESMO) 2024 in Barcelona. The company will present data demonstrating the performance of its precision oncology technology across multiple advanced tumor types. Key highlights include:
1. Guardant Reveal™ minimal residual disease test data in locally advanced rectal cancer patients (NO-CUT trial).
2. Guardant360® findings for therapy selection in advanced breast cancer and other solid tumors.
3. Guardant Infinity™ platform results for response monitoring in advanced non-small cell lung cancer (NSCLC).
The presentations aim to showcase the value of Guardant's liquid biopsy technology in informing therapy selection and treatment management across various cancer stages.
Guardant Health (Nasdaq: GH) has announced a partnership with Policlinico Gemelli, a leading Italian hospital, to establish an in-house liquid biopsy testing service in Italy. This collaboration will enable on-site analysis of Guardant360® CDx liquid biopsy tests at Policlinico Gemelli's facilities in Rome. The partnership aims to serve both clinical research and patient care needs, marking one of the first dedicated liquid biopsy testing facilities within an Italian hospital system.
Policlinico Gemelli, serving thousands of cancer patients annually, will now offer advanced diagnostics for precision oncology. This initiative aligns with Guardant Health's mission to expand access to innovative cancer diagnostics globally. In 2024, Guardant Health received IVDR certification for its Guardant360® CDx blood test, allowing for tumor mutation profiling and companion diagnostic indications in various solid cancers.
Guardant Health (Nasdaq: GH), a leading precision oncology company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY. The company's management will take part in a fireside chat on Thursday, September 5th at 11:30 a.m. ET.
Interested parties can access live and archived webcasts of the sessions on the 'Investors' section of the company's website at www.guardanthealth.com. This event provides an opportunity for Guardant Health to showcase its advancements in precision oncology and engage with industry professionals and investors.
Guardant Health (Nasdaq: GH) is set to ring the Nasdaq opening bell on August 28, 2024, celebrating the launch of their Shield™ blood test for colorectal cancer screening. This FDA-approved test offers a more comfortable alternative for early cancer detection, potentially improving survival rates.
The event marks nearly six years since Guardant's IPO bell-ringing. Co-CEO AmirAli Talasaz emphasized the significance of this milestone for the company, liquid biopsy field, and patients. The ceremony will be broadcast live at 8:30 a.m. Eastern Time, followed by a Behind the Bell interview with management.
Guardant's team will be available in New York City on August 28-29 for media interviews and investor meetings, highlighting the company's commitment to advancing precision oncology.
Guardant Health, a leader in precision oncology, announced participation in key investor conferences. The company will be present at the Canaccord Genuity 44th Annual Growth Conference in Boston, MA, with a fireside chat scheduled on Tuesday, August 13 at 10:30 a.m. ET. Additionally, Guardant Health will partake in a panel discussion on the Future of Cancer Screening at the UBS Genomic Medicine Summit in Dana Point, CA, on Wednesday, August 14 at 2:45 p.m. PT.
Live and archived webcasts of these sessions will be available on the “Investors” section of the Guardant Health website. Further details can be accessed at: www.guardanthealth.com.
Guardant Health (Nasdaq: GH) reported strong Q2 2024 financial results, with revenue increasing 29% to $177.2 million. The company raised its 2024 revenue guidance to $690-$700 million, representing 22-24% growth. Key highlights include:
1. Clinical testing volume up 14% and biopharma testing volume up 56% year-over-year
2. FDA approval of Shield as a first-line colorectal cancer screening option
3. Launch of upgraded Guardant360 on Smart Liquid Biopsy platform
4. Gross profit increased to $104.8 million, with a 59% gross margin
5. Net loss of $102.6 million, or $0.84 per share
The company's strong performance was driven by solid volume growth and improved reimbursement for Guardant360 tests.
Guardant Health (Nasdaq: GH) announced the publication of the COSMOS study in Clinical Cancer Research, validating the utility of its Guardant Reveal™ liquid biopsy test for predicting colorectal cancer recurrence. The study, involving 342 patients with stage I-III resected CRC, demonstrated:
- 81% longitudinal sensitivity for recurrence in stage II or higher colon cancer
- 98% specificity in samples from patients without recurrence
- 100% patient evaluation without tissue testing
- 5.3-month median lead time from ctDNA detection to recurrence
The study supports the use of Guardant Reveal for informing adjuvant therapy decisions and earlier recurrence detection in stage II or III colon cancer patients.
Guardant Health (Nasdaq: GH) has announced the commercial availability of its FDA-approved Shield™ blood test in the U.S. as a primary screening option for colorectal cancer (CRC). The test is now covered by Medicare for eligible beneficiaries once every three years. Shield is the first FDA-approved blood test for primary CRC screening, offering a convenient alternative to traditional methods.
Key points:
- 83% sensitivity for CRC detection with 90% specificity for advanced neoplasia
- >90% patient adherence rate
- Outperforms stool-based tests in life years gained and CRC cases averted
- Results available in about two weeks
The launch represents a significant opportunity for Guardant Health and a major step in the fight against colorectal cancer.
Guardant Health (Nasdaq: GH) announced the acceptance of its CAN-SCREEN model for publication in the Journal of Medical Economics. This health outcomes study emphasizes the importance of combining effective screening performance with high patient adherence in colorectal cancer (CRC) screening to optimize health outcomes. Unlike existing models, CAN-SCREEN accounts for both clinical efficacy and real-world adherence in predicting CRC incidence and mortality rates.
The study highlights the potential of Guardant Health's blood-based screening test, Shield™, to reduce CRC-related mortality due to its high adherence rates. The model predicts that integrating this non-invasive test into existing screening programs could significantly reduce CRC-related deaths, especially among previously unscreened populations. Patients screened with blood-based testing are predicted to gain more life years compared to those screened with FIT or mtsDNA tests.
FAQ
What is the current stock price of Guardant Health (GH)?
What is the market cap of Guardant Health (GH)?
